Status:
TERMINATED
Continuous Subcutaneous Hydrocortisone Infusion In Addison's Disease and Type 1 Diabetes
Lead Sponsor:
Haukeland University Hospital
Conditions:
Addison Disease
Type 1 Diabetes
Eligibility:
All Genders
18-70 years
Phase:
PHASE2
Brief Summary
The conventional glucocorticoid replacement therapy in primary adrenal insufficiency (Addison's disease) renders the cortisol levels unphysiological, which may cause symptoms and long-term complicatio...
Detailed Description
Treatment of Addison's disease includes glucocorticoid and mineralocorticoid replacement. Despite optimized therapy with these steroids, many patients suffer from impaired quality of life and increase...
Eligibility Criteria
Inclusion
- \- primary Addison's disease in combination with long-standing Type 1 diabetes
Exclusion
- cardiovascular disease
- active malignant disease
- pregnant women
- pharmacological treatment with glucocorticoids or drugs that interfere with cortisol metabolism (antiepileptics, rifampicin, St. Johns war, estrogens)
Key Trial Info
Start Date :
April 24 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2016
Estimated Enrollment :
4 Patients enrolled
Trial Details
Trial ID
NCT01840189
Start Date
April 24 2013
End Date
December 1 2016
Last Update
March 1 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Haukeland University Hospiatl
Bergen, Norway, 5021